The development of cell lines to produce protein biologics and gene therapies has historically been a significant challenge due to the numerous cell culture bottlenecks which exist. From the harsh conditions associated with cryopreservation and transfection, to single cell isolation for regulatory approval, to expansion to shaking conditions for bulk manufacture, the health of the cells involved can often take a substantial hit. Whether it be Chinese Hamster Ovary (CHO) cells for the production of protein therapeutics or Human Embryonic Kidney (HEK) cells for the production of new gene therapies, poor viability and viable cell densities can cause huge workflow inefficiencies. From waiting weeks for cells to recover post transfection, to seeding handfuls of plates to account for poor clonal outgrowth, scientists are constantly being faced with increased project expenditure and timelines due to cell culture limitations.
Please fill out this brief form to download this content.